| Stereochemistry | MIXED |
| Molecular Formula | C17H22I3N3O8 |
| Molecular Weight | 777.0853 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
InChI
InChIKey=NJKDOADNQSYQEV-UHFFFAOYSA-N
InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
| Molecular Formula | C17H22I3N3O8 |
| Molecular Weight | 777.0853 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Iomeprol is a nonionic, monomeric iodinated contrast medium. Iomeprol helps optimize images obtained with sophisticated multidetector computed tomography (MDCT) technology, especially for neurological, brain, liver, cardiac and vascular scanning. The mechanism of action of Iomeprol is as a X-Ray Contrast Activity. Launched by the Bracco Group in 1995, Iomeprol (Iomeron) currently is registered in more than 40 countries worldwide, including all major European markets, Japan, and major Middle East and Asian Pacific countries.
CNS Activity
Originator
Approval Year
AUC
T1/2
Doses
AEs
PubMed
Patents
Sample Use Guides
IOMERON 300 Injection: each mL of IOMERON contains 612.4 mg (equivalent to 300 mg of iodine) of iomeprol.
Radiological examination IOMERON 300 - 5 - 15 mL
Thoracic angiography IOMERON 300 5 - 50 mL
Abdominal angiography IOMERON 300 - 5 - 60 mL
Peripheral anogiography IOMERON 300 - 10 - 80 mL
Intravenous digital subtraction angiography IOMERON 300 - 10 - 50 mL
Intraarterial digital subtraction angiography IOMERON 300 - 3 - 40 mL
The dosage may be adjusted depending on the patient’s age, body weight, symptoms and purpose of use. In the case of multiple-dose administration,
a total dosage of 250 mL should not be exceeded.
Route of Administration:
Intravenous
